AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $392,213 | -12.2% | 15,847 | +0.5% | 0.00% | 0.0% |
| Q2 2023 | $446,521 | +7.9% | 15,767 | -12.5% | 0.00% | 0.0% |
| Q1 2023 | $413,850 | -18.2% | 18,017 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $505,917 | -30.3% | 18,017 | -29.8% | 0.00% | -50.0% |
| Q3 2022 | $726,000 | +27.6% | 25,677 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $569,000 | -20.5% | 25,677 | +4.4% | 0.00% | 0.0% |
| Q1 2022 | $716,000 | -11.4% | 24,587 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $808,000 | -28.8% | 24,587 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $1,135,000 | -15.8% | 24,587 | +0.5% | 0.00% | -33.3% |
| Q2 2021 | $1,348,000 | -68.7% | 24,457 | -70.7% | 0.00% | -66.7% |
| Q1 2021 | $4,308,000 | +4.1% | 83,427 | -12.6% | 0.01% | +12.5% |
| Q4 2020 | $4,137,000 | +22.1% | 95,467 | -1.4% | 0.01% | 0.0% |
| Q3 2020 | $3,388,000 | -27.4% | 96,797 | +11.0% | 0.01% | -33.3% |
| Q2 2020 | $4,664,000 | +51.4% | 87,217 | +0.5% | 0.01% | +33.3% |
| Q1 2020 | $3,081,000 | -25.6% | 86,825 | +0.2% | 0.01% | -10.0% |
| Q4 2019 | $4,139,000 | +49.2% | 86,677 | +1.2% | 0.01% | +42.9% |
| Q3 2019 | $2,775,000 | -34.7% | 85,647 | +0.5% | 0.01% | -36.4% |
| Q2 2019 | $4,250,000 | -15.1% | 85,207 | +14.7% | 0.01% | -15.4% |
| Q1 2019 | $5,008,000 | +48.0% | 74,257 | +1.2% | 0.01% | +30.0% |
| Q4 2018 | $3,384,000 | -34.4% | 73,397 | +9.7% | 0.01% | -23.1% |
| Q3 2018 | $5,162,000 | -8.3% | 66,936 | +0.2% | 0.01% | -13.3% |
| Q2 2018 | $5,628,000 | +12.4% | 66,821 | +9.1% | 0.02% | +7.1% |
| Q1 2018 | $5,007,000 | +59.3% | 61,221 | +11.3% | 0.01% | +75.0% |
| Q4 2017 | $3,143,000 | -13.0% | 54,983 | +1.6% | 0.01% | -20.0% |
| Q3 2017 | $3,614,000 | +38.7% | 54,139 | +6.9% | 0.01% | +42.9% |
| Q2 2017 | $2,605,000 | +13.0% | 50,629 | +28.3% | 0.01% | 0.0% |
| Q1 2017 | $2,305,000 | +40.4% | 39,473 | +0.3% | 0.01% | +40.0% |
| Q4 2016 | $1,642,000 | -13.5% | 39,347 | +9.5% | 0.01% | -16.7% |
| Q3 2016 | $1,898,000 | +29.4% | 35,928 | +2.6% | 0.01% | +20.0% |
| Q2 2016 | $1,467,000 | +39.7% | 35,008 | +35.4% | 0.01% | +25.0% |
| Q1 2016 | $1,050,000 | -28.7% | 25,854 | +14.0% | 0.00% | -20.0% |
| Q4 2015 | $1,472,000 | -0.9% | 22,672 | +7.7% | 0.01% | -16.7% |
| Q3 2015 | $1,486,000 | -36.1% | 21,048 | +0.7% | 0.01% | -25.0% |
| Q2 2015 | $2,324,000 | +133.3% | 20,908 | +98.0% | 0.01% | +166.7% |
| Q1 2015 | $996,000 | -7.3% | 10,562 | +10.2% | 0.00% | 0.0% |
| Q4 2014 | $1,074,000 | +82.7% | 9,587 | 0.0% | 0.00% | +50.0% |
| Q3 2014 | $588,000 | +33.9% | 9,587 | 0.0% | 0.00% | +100.0% |
| Q2 2014 | $439,000 | – | 9,587 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |